RT Book, Section A1 Valerin, Jennifer Brooke A1 Shroff, Rachna T. A2 Morita, Shane Y. A2 Balch, Charles M. A2 Klimberg, V. Suzanne A2 Pawlik, Timothy M. A2 Posner, Mitchell C. A2 Tanabe, Kenneth K. SR Print(0) ID 1145765079 T1 Treatment of Metastatic Pancreatic Cancer T2 Textbook of Complex General Surgical Oncology YR 2018 FD 2018 PB McGraw-Hill Education PP New York, NY SN 9780071793315 LK hemonc.mhmedical.com/content.aspx?aid=1145765079 RD 2024/03/29 AB Pancreatic cancer is a devastating disease that presents late and is fatal in nearly all cases. It affects about 12 per 100,000 men and women in the United States per year. This means that approximately 1.5% of U.S. men and women will be diagnosed with pancreatic cancer at some point during their lifetime. Although relatively rare compared to other cancers, comprising only 3.1% of all new cancer cases, it is the fourth leading cause of cancer death. In 2016 it was estimated that there were 53,070 new cases of pancreatic cancer and 49,620 people living with pancreatic cancer in the United States. According to Surveillance, Epidemiology, and End Results (SEER) data, new pancreas cancer cases have been rising on average 1.2% each year over the last 10 years and death rates have been rising on average 0.4% each year over the same period.1